Oppenheimer Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $95.00

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price objective dropped by stock analysts at Oppenheimer from $98.00 to $95.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price target would indicate a potential upside of 50.52% from the stock’s previous close.

Several other equities research analysts also recently issued reports on BMRN. HC Wainwright increased their price objective on shares of BioMarin Pharmaceutical from $55.00 to $60.00 and gave the stock a “neutral” rating in a research report on Monday, December 22nd. Piper Sandler reduced their price objective on BioMarin Pharmaceutical from $122.00 to $84.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Wall Street Zen cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Stifel Nicolaus reaffirmed a “hold” rating and set a $61.00 price target (down previously from $73.00) on shares of BioMarin Pharmaceutical in a research report on Thursday, November 6th. Finally, Morgan Stanley lowered their price objective on shares of BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating on the stock in a report on Tuesday, October 28th. Fifteen investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.00.

BioMarin Pharmaceutical Trading Up 0.3%

BMRN opened at $63.12 on Tuesday. The firm’s fifty day moving average is $58.31 and its two-hundred day moving average is $56.04. The firm has a market cap of $12.13 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 0.70 and a beta of 0.26. BioMarin Pharmaceutical has a twelve month low of $50.76 and a twelve month high of $73.51. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.10 and a current ratio of 4.83.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in BMRN. Wick Capital Partners LLC acquired a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at approximately $73,000. Corient Private Wealth LLC raised its holdings in BioMarin Pharmaceutical by 159.5% in the 4th quarter. Corient Private Wealth LLC now owns 15,145 shares of the biotechnology company’s stock valued at $900,000 after acquiring an additional 9,309 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in BioMarin Pharmaceutical by 1.4% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 64,069 shares of the biotechnology company’s stock valued at $3,808,000 after acquiring an additional 910 shares in the last quarter. EP Wealth Advisors LLC bought a new stake in shares of BioMarin Pharmaceutical during the 4th quarter valued at $240,000. Finally, Krensavage Asset Management LLC grew its holdings in shares of BioMarin Pharmaceutical by 29.4% during the 4th quarter. Krensavage Asset Management LLC now owns 524,786 shares of the biotechnology company’s stock worth $31,188,000 after purchasing an additional 119,336 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Announced definitive agreement to acquire Amicus Therapeutics, adding Galafold (Fabry) and Pompe product candidates — a deal the company says will accelerate and diversify revenues if closed (expected Q2’26). BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
• Positive Sentiment: Top-line strength: Q4 total revenue rose ~17% YoY (full‑year revenues +13% to ~$3.2B) led by enzyme therapies and a 26–31% lift in VOXZOGO sales — supports longer‑term growth assumptions. BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
• Positive Sentiment: Analysts reaffirm buy views: TD Cowen maintained a Buy and set a $120 price target, citing the quarter, multi‑year outlook and the Amicus deal. TD Cowen Buy Rating
• Neutral Sentiment: Management will be participating in four investor conferences in March (TD Cowen, Leerink, Jefferies, Barclays) — provides opportunities for investor Q&A and more detail on Amicus integration and 2026 outlook. Investor Conference Participation
• Neutral Sentiment: Earnings materials and call transcript/slides are available for deeper review — useful for investors to parse one‑time items, tax/ROU adjustments and the company’s guidance assumptions. Earnings Slide Deck
• Negative Sentiment: Mixed/uncertain earnings read: some outlets report EPS missed consensus (MarketBeat notes a miss vs. $0.80) while others flagged adjusted EPS beats — the disparity and one‑time items created investor confusion and pressure. MarketBeat Earnings Summary
• Negative Sentiment: Near‑term guidance and analyst moves: BioMarin provided 2026 guidance excluding Amicus contributions that was seen as slightly light by some; Bank of America lowered its price target to $97 even while keeping a Buy — a sign investors are weighing near‑term tradeoffs. BofA PT Lowered to $97
• Negative Sentiment: Market reaction: some reports noted shares edged lower after the release as investors parsed mixed EPS signals versus solid revenue and the implications of the Amicus tie‑up. Shares Edge Lower Coverage

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.